Dr. Bunn Discusses the Need to Study Drug Combinations in Lung Cancer

Video

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

Paul A. Bunn, Jr., MD, distinguished professor, University of Colorado, Lung Cancer: Giant of Cancer Care, discusses the need to study drug combinations in lung cancer.

The goal of early lung cancer pioneers, Bunn says, was to cure cancer with chemotherapies that shrank the disease. The strategy at the time was to combine drugs in order to get a complete remission that would last.

Today, lung cancer doctors have TKIs that are very specific and elicit high response rates – but they don’t cure anybody, Bunn says. There are many scientifically rational combinations that could be studied, he says, but these trials need to start happening.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine